title: Interactions between HIV-1 Gag molecules in solution: an inositol phosphate-mediated switch.
abstract: Retrovirus particle assembly is mediated by the Gag protein. Gag is a multi-domain protein containing discrete domains connected by flexible linkers. When recombinant HIV-1 Gag protein (lacking myristate at its N terminus and the p6 domain at its C terminus) is mixed with nucleic acid, it assembles into virus-like particles (VLPs) in a fully defined system in vitro. However, this assembly is defective in that the radius of curvature of the VLPs is far smaller than that of authentic immature virions. This defect can be corrected to varying degrees by addition of inositol phosphates to the assembly reaction. We have now explored the binding of inositol hexakisphosphate (IP6) to Gag and its effects upon the interactions between Gag protein molecules in solution. Our data indicate that basic regions at both ends of the protein contribute to IP6 binding. Gag is in monomer-dimer equilibrium in solution, and mutation of the previously described dimer interface within its capsid domain drastically reduces Gag dimerization. In contrast, when IP6 is added, Gag is in monomer-trimer rather than monomer-dimer equilibrium. The Gag protein with a mutation at the dimer interface also remains almost exclusively monomeric in IP6; thus the "dimer interface" is essential for the trimeric interaction in IP6. We discuss possible explanations for these results, including a change in conformation within the capsid domain induced by the binding of IP6 to other domains within the protein. The participation of both ends of Gag in IP6 interaction suggests that Gag is folded over in solution, with its ends near each other in three-dimensional space; direct support for this conclusion is provided in a companion manuscript. As Gag is an extended rod in immature virions, this apparent proximity of the ends in solution implies that it undergoes a major conformational change during particle assembly.
authors.affiliation: HIV Drug Resistance Program, National Cancer Institute-Frederick, Frederick, MD 21702, USA.
authors.forename: Siddhartha A K
authors.initials: SA
authors.lastname: Datta
authors.forename: Zhuojun
authors.initials: Z
authors.lastname: Zhao
authors.forename: Patrick K
authors.initials: PK
authors.lastname: Clark
authors.forename: Sergey
authors.initials: S
authors.lastname: Tarasov
authors.forename: Jerry N
authors.initials: JN
authors.lastname: Alexandratos
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Campbell
authors.forename: Mamuka
authors.initials: M
authors.lastname: Kvaratskhelia
authors.forename: Jacob
authors.initials: J
authors.lastname: Lebowitz
authors.forename: Alan
authors.initials: A
authors.lastname: Rein
mesh_terms: D006916:5-Hydroxytryptophan / Q000378:metabolism; D001665:Binding Sites; D002850:Chromatography, Gel; D019281:Dimerization; D015683:Gene Products, gag / Q000032:analysis / Q000737:chemistry / Q000378:metabolism*; D015497:HIV-1 / Q000378:metabolism*; D013058:Mass Spectrometry; D050505:Mutant Proteins / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D009154:Mutation / Q000235:genetics; D010833:Phytic Acid / Q000378:metabolism*; D011485:Protein Binding; D023302:Protein Footprinting; D020836:Protein Structure, Quaternary; D017434:Protein Structure, Tertiary; D012996:Solutions; D014316:Tritium
chemical_list: D015683:Gene Products, gag; D050505:Mutant Proteins; D012996:Solutions; D014316:Tritium; D010833:Phytic Acid; D006916:5-Hydroxytryptophan